Editorial scientific illustration connecting Coptis root and berberine with metabolic sensing and chromatin
Geroprotect Blog

Geroprotect research note · Evidence review

From Coptis to the Clock

Berberine, alpha-ketoglutarate and curcumin — how nutrient sensing reaches the epigenome, and what the 2026 ITP result means

Abstract

Berberine has a comparatively substantial human evidence base for several metabolic markers, while alpha-ketoglutarate (AKG) and curcumin illustrate why mechanism, biomarkers, healthspan and lifespan must not be treated as interchangeable. This research note follows a plausible path from AMPK and cellular NAD+ to enzymes that regulate DNA and histone methylation, then tests that narrative against the strongest negative evidence: the 2026 Interventions Testing Program result in which AKG did not extend mouse lifespan.

01 · Context

From a medicinal root to a modern metabolic question

Coptis species have a long history in traditional medicine, and their yellow colour comes from alkaloids that include berberine. That history is interesting, but duration of use is not a substitute for controlled evidence. The useful modern question is narrower: what has berberine actually done in randomized human trials, and how securely can those results be connected to the molecular pathways discussed in aging research?

A 2025 systematic review identified 12 randomized, placebo-controlled trials involving 889 people with components of metabolic syndrome. Across the pooled studies, berberine was associated with lower fasting plasma glucose, two-hour oral-glucose-tolerance values, triglycerides, LDL cholesterol, total cholesterol, waist circumference and BMI. The analysis did not find significant overall effects on HDL cholesterol or blood pressure. The authors also reported heterogeneity and limitations in the underlying evidence, so these are pooled changes in individual risk markers — not proof that berberine reverses metabolic syndrome or prevents clinical events.

−0.515 mmol/Lfasting plasma glucose
−0.495 mmol/LLDL cholesterol
−3.27 cmwaist circumference
No clear effectblood pressure or HDL overall

A broader 2024 meta-analysis included 50 trials and 4,150 participants, but mixed berberine used alone with combination treatment and found important quality limitations. One small 2008 pilot compared berberine with metformin in 36 adults newly diagnosed with type 2 diabetes and observed similar changes in some glycaemic measures. That exploratory study was not designed to establish large-scale equivalence. Berberine should not be described as a proven substitute for metformin or prescribed care.

Evidence level: human meta-analyses of mostly short trials for intermediate metabolic outcomes; no evidence here for lifespan extension.

02 · Mechanism

AMPK, cellular NAD+ and the limit of a mechanistic bridge

AMP-activated protein kinase (AMPK) helps cells respond to energetic stress. In broad terms, it can shift metabolism away from energy-consuming synthesis and towards processes that generate or conserve energy. Berberine is often described as an AMPK activator. A 2020 experiment used CRISPR to remove AMPKα1 from HepG2 liver-derived cells and found that several berberine responses depended on that subunit. This is useful mechanistic evidence, but it is a cell experiment — not confirmation of the same causal chain in people taking a supplement.

In 2009, Cantó and colleagues showed that AMPK could influence cellular NAD+ metabolism and SIRT1 activity, with downstream effects on PGC-1α and FOXO proteins. The work established an important connection between energy sensing and NAD+-dependent signalling in cell and mouse models.

The pathway is a biologically plausible bridge, not a clinical result. No controlled human trial has shown that combining berberine with an NAD+ precursor improves healthspan, lifespan or any validated aging endpoint beyond the effects of either component alone.

This distinction matters. A pathway can justify a research hypothesis; it cannot establish synergy. Claims about a “stack” must remain conditional until the exact combination, dose and population are tested.

03 · Epigenetic chemistry

AKG connects metabolism to enzymes that edit chromatin

Alpha-ketoglutarate is both a tricarboxylic-acid-cycle intermediate and a co-substrate for a large family of 2-oxoglutarate-dependent dioxygenases. Members include TET enzymes involved in DNA demethylation and JmjC-domain enzymes involved in histone demethylation. Their catalytic chemistry uses AKG, ferrous iron and oxygen; ascorbate can help maintain iron in the required state.

That is established enzymology. A much larger claim sometimes gets attached to it: that taking more AKG will necessarily increase enzyme activity, erase age-associated marks or “reset” an epigenetic clock. The chemistry alone cannot support that conclusion. Oral intake, absorption, tissue exposure, intracellular concentration, feedback regulation and the availability of other substrates all stand between a capsule and an enzyme in a particular human cell.

04 · The replication test

The 2026 ITP result: AKG did not extend mouse lifespan

A widely discussed 2020 study gave calcium AKG to mice beginning at 18 months of age. Female median lifespan increased by 16.6% and 90th-percentile lifespan by 19.7%; the male lifespan result was not statistically significant. Frailty scores improved in both sexes. The study prompted serious interest, but it also had industry and patent-related competing interests and needed independent replication.

The NIA Interventions Testing Program (ITP) is designed for exactly that purpose: genetically heterogeneous mice, parallel testing at three sites and harmonized protocols. In a paper published online on 17 March 2026, none of 11 tested interventions extended lifespan at the evaluated doses and schedules. AKG was among the null results.

The correct interpretation has two parts:

  • The ITP result materially weakens the claim that AKG reliably extends mouse lifespan.
  • It does not directly retest every frailty measure or every possible dose, formulation and schedule from the earlier study.

Those qualifications should not be used to wave away the null result. They define its scope. The earlier healthspan signals remain hypotheses worth replicating; they are not established benefits, and neither mouse study demonstrates a human outcome.

2020 · Single research programme

Positive but uneven

Late-life calcium AKG improved female lifespan and frailty measures; male lifespan was not significantly extended.

2026 · Three-site ITP

No lifespan extension

AKG did not extend lifespan in heterogeneous mice at the tested conditions.

05 · Biomarkers

Epigenetic clocks can move without proving rejuvenation

A 2021 retrospective analysis associated a calcium-AKG-containing formulation with an average reduction in measured DNA-methylation age. It had no randomized control group, used a single commercial clock and included industry involvement. A 2025 single-arm study reported changes across several clocks after a programme that combined multiple ingredients with walking and mindfulness. With no placebo arm, the contribution of AKG — or any one component — cannot be isolated.

Epigenetic clocks are statistical biomarkers built from patterns of DNA methylation. They may help researchers track biological variation, but a lower clock value is not yet a validated surrogate for living longer, avoiding disease or maintaining function. Clock movement should therefore be reported as clock movement, not as years of life regained.

06 · Curcumin

A noisy laboratory molecule with mixed clinical evidence

Curcumin is a cautionary example in both directions. Medicinal chemists have documented its tendency to interfere with assays, aggregate, react nonspecifically and produce attractive but misleading laboratory signals. That makes many target-level claims unreliable.

Human evidence should still be assessed on its own merits. An umbrella review of randomized trials reported reductions in several inflammatory biomarkers, while an earlier meta-analysis found no significant reduction in a number of those same markers. More recent indication-specific reviews also report substantial heterogeneity and often low or very low certainty. Formulation, dose, study population and bias appear to matter.

The defensible conclusion is neither “curcumin does nothing” nor “curcumin is proven anti-inflammatory.” Some pooled human outcomes are favourable, but results are mixed, often biomarker-based and do not establish an effect on aging or lifespan.

07 · Safety

Berberine is biologically active enough to interact with medicines

Berberine commonly causes gastrointestinal effects and can interact with medicines. In a small human crossover study, two weeks of berberine altered the activity of CYP2D6, CYP2C9 and CYP3A4 — enzyme systems involved in processing many drugs. Clinical research has also documented an interaction with cyclosporine. The exact significance varies by drug, dose and person, but the risk is real.

People who use prescription medicines, are pregnant or breastfeeding, are preparing for a procedure, or have a medical condition should speak with a qualified clinician or pharmacist before considering berberine. It should not be given to infants. This article does not recommend starting, stopping or replacing any treatment.

08 · Reading the whole record

What we know, what we infer, and what remains unknown

StatementEvidence boundary
Berberine improves some metabolic markersSupported by pooled short-term human trials, with heterogeneity and study-quality limitations.
AMPK can connect energy sensing to NAD+ and SIRT1Strong mechanistic evidence, primarily from cellular and animal experiments.
AKG is used by TET and JmjC enzymesEstablished biochemistry; oral supplementation effects on human epigenetic aging are unproven.
AKG extends lifespanNot established. One mouse programme was positive in females; the rigorous 2026 ITP test was negative.
A lower epigenetic-clock age means longer lifeUnproven. Current clocks are biomarkers, not validated surrogate outcomes.
The Geroprotect ingredient combination is synergisticA formulation rationale, not a demonstrated clinical effect; the combination has not been tested against its components.

Natural compounds are difficult and expensive to test over decades, particularly when exclusivity is limited. That explains some gaps in the literature; it does not fill them. The honest approach is to publish positive, null and conflicting findings together, distinguish mechanism from outcome and update conclusions when better evidence arrives.

Questions

Frequently asked questions

Is berberine as effective as metformin?

No equivalence has been established at scale. One small pilot found similar changes in some measures, but metformin and berberine are different substances with different evidence, quality control and interaction profiles. Prescribed treatment should never be replaced on the basis of this comparison.

Did the ITP prove that AKG has no value?

It showed that AKG did not extend mouse lifespan under the tested conditions. It did not settle every possible healthspan endpoint, dose or formulation. It nevertheless shifts the evidence against broad lifespan claims.

Does AKG reverse epigenetic aging?

That has not been demonstrated. AKG participates in relevant enzyme chemistry, and uncontrolled studies have reported clock changes, but there is no robust evidence that oral AKG reverses human aging.

Why combine berberine with NAD+ precursors?

AMPK and NAD+ biology provide a testable formulation rationale. No controlled human study has shown that this combination is synergistic or improves a validated aging outcome.

Sources

References

  1. Efficacy and safety of berberine on components of metabolic syndrome: systematic review and meta-analysis of placebo-controlled RCTs. Frontiers in Pharmacology. 2025. PMID 40740996.
  2. Effects of administering berberine alone or in combination on type 2 diabetes: systematic review and meta-analysis. Frontiers in Pharmacology. 2024. PMID 39640489.
  3. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008. PMID 18442638.
  4. Berberine improves glucose and lipid metabolism in HepG2 cells through AMPKα1 activation. Frontiers in Pharmacology. 2020. PMID 32457629.
  5. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009. PMID 19262508.
  6. The role of 2-oxoglutarate-dependent dioxygenases in epigenetic regulation. 2020. PMID 33092942.
  7. Vitamin C and TET-mediated DNA demethylation: a review of catalytic context. 2023. PMID 37263060.
  8. Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice. Cell Metabolism. 2020. PMID 32877690.
  9. Testing of eleven compounds for effects on lifespan in genetically heterogeneous mice. GeroScience. 2026. PMID 41843349.
  10. Retrospective DNA-methylation-age analysis of a multi-ingredient calcium-AKG formulation. Aging. 2021. PMID 34847066.
  11. Single-arm lifestyle and multi-ingredient intervention reporting epigenetic-clock changes. Aging. 2025.
  12. The essential medicinal chemistry of curcumin. Journal of Medicinal Chemistry. 2017. PMID 28074653.
  13. Curcumin supplementation and inflammatory biomarkers: an umbrella meta-analysis. 2023. PMID 36700039.
  14. Effects of curcumin on inflammatory markers: systematic review and meta-analysis. 2019. PMID 31121255.
  15. Repeated administration of berberine inhibits cytochromes P450 in humans. European Journal of Clinical Pharmacology. 2012. PMID 21870106.
  16. Pharmacokinetic interaction between berberine and cyclosporine in renal-transplant recipients. European Journal of Clinical Pharmacology. 2005. PMID 16133554.
  17. Berberine: safety, side effects and interactions. US National Center for Complementary and Integrative Health.

Quality you can check

Every badge links to the document behind it: manufacturer certificates, certificates of analysis for all 26 actives, and our own promises about the formula.

Huazhen Biotechnology (Shenzhen) holds ISO 22000:2018 certificate 015FSMS2400550 and HACCP certificate 015HACCP2400460, both valid until 2 December 2027. These are manufacturer system papers, not a product certificate. The earlier papers 150FSMS2200001 and 150HACCP2200001 ended in March 2025 and are not shown as valid. Halal certificates cover raw materials from our suppliers; Geroprotect Essentials is not registered as a halal product. Food supplement. Read the current product label before use.

Bought from Geroprotect? Leave an honest review:Review us on TrustpilotReview us on GoogleReview on Amazon.aeReviews are optional and never rewarded. More about reviews.
Scroll to Top